SCHEMBL167579

SCHEMBL167579

CCNc1cc(-c2ccccc2)n[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.53
POLB P06746 1/20 0.50
RAB9A P51151 1/20 0.50
CHEK1 O14757 1/20 0.47
RET P07949 1/20 0.47
PDGFRB P09619 1/20 0.47
PIM1 P11309 1/20 0.47
PDGFRA P16234 1/20 0.47
GSK3B P49841 1/20 0.47
RPS6KA3 P51812 1/20 0.47
LIMK1 P53667 1/20 0.47
CDK5 Q00535 1/20 0.47
TYRO3 Q06418 1/20 0.47
MAPK14 Q16539 1/20 0.47
LRRK2 Q5S007 1/20 0.47
AURKB Q96GD4 1/20 0.47
CLK4 Q9HAZ1 1/20 0.47
DYRK1B Q9Y463 1/20 0.47
GAA P10253 1/20 0.46
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9054189 0.87 L3MBTL1 (0.50) L3MBTL1POLBRAB9ACHEK1RET
SCHEMBL6566494 0.85 RAB9A (0.48) POLBRAB9ARETLMNATP53
SCHEMBL9051736 0.84 TLR8 (0.51) L3MBTL1POLBRAB9ACHEK1RET
SCHEMBL10599732 0.83 RAB9A (0.51) L3MBTL1POLBRAB9ACHEK1RET
SCHEMBL4948626 0.80 L3MBTL1 (0.58) L3MBTL1POLBRAB9ACHEK1RET
SCHEMBL14217911 0.78 L3MBTL1 (0.47) L3MBTL1POLBRAB9ACHEK1RET
SCHEMBL7395253 0.77 POLB (0.55) L3MBTL1POLBRAB9ACHEK1RET
SCHEMBL12282618 0.76 MAPT (0.53) L3MBTL1POLBRAB9ALMNATP53
SCHEMBL11886170 0.76 ADORA3 (0.55) L3MBTL1POLBRAB9ACHEK1RET
SCHEMBL5534364 0.75 GAA (0.62) L3MBTL1POLBRAB9ACHEK1RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1996034591-A1 DIAMINOPYRAZOLE-CONTAINING COMPOSITIONS FOR COLOURING KERATIN FIBRES, COLOURING PROCESS, NOVEL DIAMINOPYRAZOLES AND METHOD FOR THEIR PREPARATION L'OREAL (FR) 1996-11-07 WO claimed
CN-103189378-B As the Pyrazolopyridine ketone derivatives of LPA receptor antagonist MERCK PATENT GMBH (DE) 2016-03-02 CN disclosed
US-9067938-B2 Pyrazolopyridinone derivatives as LPA receptor antagonists MERCK PATENT GMBH (DE) 2015-06-30 US disclosed
US-9067938-B2 Pyrazolopyridinone derivatives as LPA receptor antagonists MERCK PATENT GMBH (DE) 2015-06-30 US disclosed
US-9067938-B2 Pyrazolopyridinone derivatives as LPA receptor antagonists MERCK PATENT GMBH (DE) 2015-06-30 US disclosed
US-20140350046-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2014-11-27 US disclosed
US-20140350046-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2014-11-27 US disclosed
US-20140350046-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2014-11-27 US disclosed
EP-2611808-B1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2014-11-12 EP disclosed
EP-2611808-B1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2014-11-12 EP disclosed
US-8859775-B2 Pyrazolopyridinone derivatives as LPA receptor antagonists MERCK PATENT GMBH (DE) 2014-10-14 US disclosed
EP-2611808-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS Merck Patent GmbH (DE) 2013-07-10 EP disclosed
CN-103189378-A Pyrazolopyridinone derivatives as LPA receptor antagonists MERCK PATENT GMBH 2013-07-03 CN disclosed
US-20130165478-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-06-27 US disclosed
US-20130165478-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-06-27 US disclosed
US-20130165478-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-06-27 US disclosed
WO-2012028243-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2012-03-08 WO disclosed
WO-2012028243-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2012-03-08 WO disclosed
EP-1404288-A2 COMPOSITION FOR OXIDATION DYEING OF KERATINOUS FIBRES COMPRISING A AMINO PYRAZOLE AND A CELLULOSE COMPOUND L'OREAL (FR) 2004-04-07 EP disclosed
WO-2002051372-A2 COMPOSITION FOR OXIDATION DYEING OF KERATINOUS FIBRES COMPRISING A AMINO PYRAZOLE AND A CELLULOSE COMPOUND L'OREAL (FR) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140350046-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 L3MBTL1 3955/4885POLB 2887/4885RAB9A 1419/4885
US-20130165478-A1 PYRAZOLOPYRIDINONE DERIVATIVES AS LPA RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 L3MBTL1 3955/4885POLB 2887/4885RAB9A 1419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.